A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo

Study Title
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo
Teva Identifier
TV53408-IMM-10209
ClinicalTrials.gov Identifier
NCT06625177
Study Status
Recruiting
Trial Condition(s)
Vitiligo
Interventions
Drug: TEV-53408
Study Description
The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.
Print

Participation criteria and map of study locations
allergy-icon

Key Participation Requirements

Gender
Female, Male
Age group
Adult, Older Adult
Age Range
18 Years to 75 Years
Trial Duration
November 11, 2024 - June 05, 2027
Phase
Phase 1

Study Type

Interventional